WEBSITE BSE:500087 NSE: CIPLA LTD. Inc. Year: 1935 Industry: Pharmaceuticals & Drugs
Last updated: 15:59
Cipla Limited is an primarily India-based enterprise, usually engaged in the commercial enterprise of pharmaceuticals. The Company's segments consist of Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in growing, manufacturing, promoting and distributing widespread or branded accepted medicines, in addition to Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a customer healthcare, Biosimilars and distinctiveness enterprise. Its product portfolio spans complex gene...Read More
Cipla Limited is an primarily India-based enterprise, usually engaged in the commercial enterprise of pharmaceuticals. The Company's segments consist of Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in growing, manufacturing, promoting and distributing widespread or branded accepted medicines, in addition to Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a customer healthcare, Biosimilars and distinctiveness enterprise. Its product portfolio spans complex generics, as well as drugs within the breathing, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). The Company's geographical segments include India, America, South Africa and Rest of the World. The Company has its community of manufacturing, buying and selling and different incidental operations in India and International markets. The Company has total of 46 manufacturing sites. ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹112886 Cr.
Stock P/E 21.3
P/B 3.4
Current Price ₹1397.5
Book Value ₹ 407.5
Face Value 2
52W High ₹1672.2
Dividend Yield 1.14%
52W Low ₹ 1310.1
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 6329 | 6678 | 6604 | 6163 | 6694 | 7051 | 7073 | 6730 | 6957 | 7589 |
| Other Income | 136 | 176 | 185 | 249 | 160 | 191 | 222 | 289 | 259 | 269 |
| Total Income | 6465 | 6854 | 6788 | 6413 | 6854 | 7242 | 7295 | 7019 | 7216 | 7858 |
| Total Expenditure | 4835 | 4944 | 4856 | 4847 | 4978 | 5165 | 5084 | 5192 | 5179 | 5695 |
| Operating Profit | 1630 | 1910 | 1932 | 1565 | 1876 | 2076 | 2211 | 1827 | 2037 | 2164 |
| Interest | 16 | 26 | 30 | 18 | 18 | 15 | 15 | 14 | 14 | 13 |
| Depreciation | 239 | 290 | 233 | 288 | 247 | 272 | 280 | 309 | 253 | 297 |
| Exceptional Income / Expenses | 0 | 0 | -195 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1375 | 1594 | 1474 | 1259 | 1611 | 1789 | 1916 | 1504 | 1770 | 1854 |
| Provision for Tax | 378 | 438 | 405 | 325 | 435 | 483 | 332 | 279 | 478 | 500 |
| Profit After Tax | 997 | 1156 | 1069 | 934 | 1176 | 1306 | 1584 | 1225 | 1292 | 1353 |
| Adjustments | -1 | -25 | -13 | 5 | 1 | -3 | -13 | -3 | 6 | -2 |
| Profit After Adjustments | 996 | 1131 | 1056 | 939 | 1178 | 1303 | 1571 | 1222 | 1298 | 1351 |
| Adjusted Earnings Per Share | 12.3 | 14 | 13.1 | 11.6 | 14.6 | 16.1 | 19.4 | 15.1 | 16.1 | 16.7 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 11345 | 13595 | 14394 | 15156 | 16362 | 17132 | 19160 | 21763 | 22753 | 25774 | 27548 | 28349 |
| Other Income | 166 | 208 | 229 | 358 | 477 | 369 | 270 | 322 | 512 | 747 | 862 | 1039 |
| Total Income | 11511 | 13803 | 14623 | 15513 | 16839 | 17501 | 19429 | 22085 | 23265 | 26521 | 28409 | 29388 |
| Total Expenditure | 9184 | 11115 | 11919 | 12329 | 13265 | 13951 | 14911 | 17251 | 17763 | 19483 | 20420 | 21150 |
| Operating Profit | 2327 | 2688 | 2704 | 3184 | 3574 | 3550 | 4518 | 4834 | 5502 | 7038 | 7990 | 8239 |
| Interest | 168 | 207 | 159 | 114 | 168 | 197 | 161 | 106 | 110 | 90 | 62 | 56 |
| Depreciation | 505 | 754 | 1323 | 1323 | 1326 | 1175 | 1068 | 1052 | 1172 | 1051 | 1107 | 1139 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -78 | 0 | 0 | 0 | -182 | -182 | -195 | 0 | 0 |
| Profit Before Tax | 1654 | 1727 | 1222 | 1669 | 2079 | 2178 | 3290 | 3493 | 4038 | 5702 | 6821 | 7044 |
| Provision for Tax | 400 | 332 | 180 | 250 | 570 | 631 | 889 | 934 | 1203 | 1547 | 1530 | 1589 |
| Profit After Tax | 1254 | 1395 | 1042 | 1419 | 1510 | 1547 | 2401 | 2559 | 2835 | 4155 | 5291 | 5454 |
| Adjustments | -73 | -35 | -36 | -9 | 18 | -0 | 4 | -43 | -34 | -34 | -19 | -12 |
| Profit After Adjustments | 1181 | 1360 | 1006 | 1411 | 1528 | 1547 | 2405 | 2517 | 2802 | 4122 | 5273 | 5442 |
| Adjusted Earnings Per Share | 14.7 | 16.9 | 12.5 | 17.5 | 19 | 19.2 | 29.8 | 31.2 | 34.7 | 51.1 | 65.3 | 67.3 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 7% | 8% | 10% | 9% |
| Operating Profit CAGR | 14% | 18% | 18% | 13% |
| PAT CAGR | 27% | 27% | 28% | 15% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -3% | 10% | 12% | 9% |
| ROE Average | 18% | 16% | 15% | 13% |
| ROCE Average | 24% | 22% | 20% | 16% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 10801 | 11516 | 12544 | 14229 | 15012 | 15763 | 18327 | 20842 | 23408 | 26706 | 31193 |
| Minority's Interest | 180 | 350 | 438 | 352 | 332 | 294 | 259 | 276 | 306 | 96 | 96 |
| Borrowings | 309 | 222 | 3645 | 3662 | 3830 | 2369 | 1203 | 416 | 0 | 0 | 12 |
| Other Non-Current Liabilities | 2108 | 1185 | 868 | 597 | 816 | 603 | 457 | 205 | 184 | 82 | -43 |
| Total Current Liabilities | 3881 | 7776 | 3374 | 3832 | 3772 | 4393 | 4591 | 4913 | 5033 | 5246 | 5484 |
| Total Liabilities | 17281 | 21049 | 20869 | 22673 | 23762 | 23423 | 24837 | 26652 | 29007 | 32130 | 36742 |
| Fixed Assets | 6830 | 9368 | 9490 | 9949 | 9547 | 9559 | 9394 | 9622 | 9101 | 9494 | 9895 |
| Other Non-Current Assets | 2860 | 2840 | 2574 | 1910 | 1789 | 2158 | 2234 | 2303 | 2631 | 3195 | 3559 |
| Total Current Assets | 7591 | 8841 | 8736 | 10814 | 12425 | 11704 | 13181 | 14711 | 16805 | 19392 | 23249 |
| Total Assets | 17281 | 21049 | 20869 | 22673 | 23762 | 23423 | 24837 | 26652 | 29007 | 32130 | 36742 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 176 | 546 | 858 | 610 | 853 | 508 | 649 | 790 | 658 | 561 | 512 |
| Cash Flow from Operating Activities | 1173 | 1741 | 2382 | 1463 | 1691 | 3068 | 3755 | 3326 | 3238 | 4134 | 5005 |
| Cash Flow from Investing Activities | -941 | -4523 | -1310 | -854 | -1669 | 104 | -2387 | -1872 | -2389 | -2988 | -3691 |
| Cash Flow from Financing Activities | 165 | 3104 | -1326 | -385 | -349 | -2949 | -1240 | -1600 | -958 | -1200 | -1293 |
| Net Cash Inflow / Outflow | 397 | 322 | -254 | 223 | -326 | 224 | 129 | -146 | -109 | -55 | 21 |
| Closing Cash & Cash Equivalent | 564 | 858 | 610 | 853 | 508 | 742 | 790 | 658 | 561 | 512 | 543 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 14.71 | 16.93 | 12.51 | 17.52 | 18.96 | 19.18 | 29.82 | 31.19 | 34.71 | 51.05 | 65.29 |
| CEPS(Rs) | 21.91 | 26.76 | 29.4 | 34.06 | 35.2 | 33.76 | 43.02 | 44.76 | 49.65 | 64.49 | 79.22 |
| DPS(Rs) | 2 | 2 | 2 | 3 | 3 | 4 | 5 | 5 | 8.5 | 13 | 16 |
| Book NAV/Share(Rs) | 133.38 | 142.23 | 155.15 | 175.92 | 185.62 | 194.85 | 226.73 | 257.78 | 289.24 | 329.72 | 384.84 |
| Core EBITDA Margin(%) | 18.87 | 17.98 | 16.92 | 18.57 | 12.95 | 11.72 | 15.05 | 15.18 | 16.13 | 17.76 | 19.24 |
| EBIT Margin(%) | 15.91 | 14.02 | 9.44 | 11.72 | 9.4 | 8.76 | 12.22 | 12.11 | 13.41 | 16.35 | 18.58 |
| Pre Tax Margin(%) | 14.44 | 12.52 | 8.35 | 10.97 | 8.7 | 8.03 | 11.66 | 11.75 | 13.05 | 16.1 | 18.42 |
| PAT Margin (%) | 10.95 | 10.12 | 7.13 | 9.33 | 6.31 | 5.7 | 8.51 | 8.61 | 9.17 | 11.73 | 14.29 |
| Cash Profit Margin (%) | 15.36 | 15.59 | 16.17 | 18.02 | 11.86 | 10.03 | 12.29 | 12.15 | 12.95 | 14.7 | 17.27 |
| ROA(%) | 7.85 | 7.28 | 4.97 | 6.52 | 6.5 | 6.56 | 9.95 | 9.94 | 10.19 | 13.59 | 15.36 |
| ROE(%) | 12.1 | 12.61 | 8.72 | 10.65 | 10.37 | 10.09 | 14.13 | 13.1 | 12.85 | 16.63 | 18.34 |
| ROCE(%) | 15.33 | 13.24 | 8.28 | 10.2 | 11.94 | 12.53 | 17.85 | 17.24 | 18.19 | 22.77 | 23.64 |
| Receivable days | 57.94 | 57.62 | 61.36 | 67.94 | 55.36 | 54.1 | 47.44 | 42.19 | 44.13 | 45.49 | 50.64 |
| Inventory Days | 106.36 | 100.43 | 90.98 | 90.29 | 61.13 | 56.12 | 58.49 | 61.53 | 61.98 | 53.56 | 53.61 |
| Payable days | 103.91 | 104.98 | 104.58 | 123.84 | 128.32 | 128.84 | 107.95 | 98.28 | 111.52 | 103.64 | 108.56 |
| PER(x) | 48.36 | 30.26 | 47.35 | 31.01 | 27.91 | 22.05 | 27.34 | 32.65 | 25.95 | 29.28 | 22.08 |
| Price/Book(x) | 5.33 | 3.6 | 3.82 | 3.09 | 2.85 | 2.17 | 3.6 | 3.95 | 3.11 | 4.53 | 3.75 |
| Dividend Yield(%) | 0.28 | 0.39 | 0.34 | 0.55 | 0.57 | 0.95 | 0.61 | 0.49 | 0.94 | 0.87 | 1.11 |
| EV/Net Sales(x) | 5.13 | 3.35 | 3.55 | 3.09 | 2.83 | 2.1 | 3.45 | 3.73 | 3.15 | 4.66 | 4.2 |
| EV/Core EBITDA(x) | 25.03 | 16.92 | 18.91 | 14.72 | 12.97 | 10.12 | 14.63 | 16.77 | 13.02 | 17.06 | 14.48 |
| Net Sales Growth(%) | 11.52 | 19.83 | 5.88 | 5.29 | 7.96 | 4.7 | 11.84 | 13.59 | 4.55 | 13.28 | 6.88 |
| EBIT Growth(%) | -10.03 | 6.1 | -28.55 | 29.11 | 26.01 | 5.69 | 45.26 | 4.31 | 15.23 | 39.63 | 18.84 |
| PAT Growth(%) | -11.47 | 11.26 | -25.3 | 36.16 | 6.36 | 2.48 | 55.23 | 6.59 | 10.78 | 46.55 | 27.33 |
| EPS Growth(%) | -14.96 | 15.11 | -26.1 | 40.05 | 8.23 | 1.16 | 55.46 | 4.61 | 11.28 | 47.06 | 27.89 |
| Debt/Equity(x) | 0.16 | 0.46 | 0.33 | 0.29 | 0.29 | 0.18 | 0.1 | 0.04 | 0.02 | 0.01 | 0 |
| Current Ratio(x) | 1.96 | 1.14 | 2.59 | 2.82 | 3.29 | 2.66 | 2.87 | 2.99 | 3.34 | 3.7 | 4.24 |
| Quick Ratio(x) | 0.99 | 0.65 | 1.56 | 1.77 | 2.24 | 1.67 | 1.85 | 1.91 | 2.31 | 2.7 | 3.21 |
| Interest Cover(x) | 10.83 | 9.36 | 8.67 | 15.61 | 13.34 | 12.04 | 21.47 | 33.85 | 37.87 | 64.44 | 111 |
| Total Debt/Mcap(x) | 0.03 | 0.13 | 0.09 | 0.09 | 0.1 | 0.08 | 0.03 | 0.01 | 0.01 | 0 | 0 |
| # | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 33.4 | 33.4 | 33.4 | 33.4 | 30.86 | 30.86 | 29.13 | 29.13 | 29.13 | 29.13 |
| FII | 25.44 | 25.69 | 25.68 | 25.77 | 27.77 | 28.74 | 26.6 | 26.22 | 25.19 | 24.47 |
| DII | 24.22 | 24.06 | 24.22 | 24.3 | 24.84 | 24.04 | 27.59 | 28.09 | 29.19 | 30.15 |
| Public | 16.73 | 16.64 | 16.5 | 16.32 | 16.37 | 16.16 | 16.49 | 16.34 | 16.27 | 15.95 |
| Others | 0.2 | 0.21 | 0.21 | 0.21 | 0.16 | 0.21 | 0.2 | 0.22 | 0.22 | 0.29 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 26.96 | 26.96 | 26.96 | 26.96 | 24.92 | 24.92 | 23.53 | 23.53 | 23.53 | 23.53 |
| FII | 20.54 | 20.74 | 20.73 | 20.81 | 22.42 | 23.21 | 21.48 | 21.18 | 20.35 | 19.77 |
| DII | 19.55 | 19.43 | 19.55 | 19.62 | 20.06 | 19.41 | 22.28 | 22.69 | 23.58 | 24.36 |
| Public | 13.51 | 13.43 | 13.32 | 13.18 | 13.22 | 13.05 | 13.31 | 13.2 | 13.14 | 12.88 |
| Others | 0.16 | 0.17 | 0.17 | 0.17 | 0.13 | 0.17 | 0.16 | 0.17 | 0.18 | 0.24 |
| Total | 80.72 | 80.73 | 80.74 | 80.74 | 80.75 | 80.76 | 80.76 | 80.76 | 80.78 | 80.78 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
